SARASOTA, Fla.--(BUSINESS WIRE)--RPS Diagnostics, Inc. (RPS®) today announces that Health Canada issued a Medical Device License for FebriDx® – a rapid, in-office test that uses a fingerstick blood ...
RPS Diagnostics, a Sarasota-based commercial diagnostic developer, manufacturer, and marketer of point-of-care diagnostic tests, and Lumos Diagnostics, a California-based, full-service, point-of-care ...
Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
FebriDx is a rapid, disposable, in-office test that helps identify and differentiate a clinically significant immune response to viral and/or bacterial acute febrile respiratory infection at the point ...
Please provide your email address to receive an email when new articles are posted on . Rapid Pathogen Screening Inc. announced that the U.S. Food and Drug Administration has approved InflammaDry, a ...
LAKEWOOD RANCH — Local biotech company RPS Diagnostics has merged with a California firm that will focus on the international launch of RPS's infections test. Lumos Diagnostics has acquired all of the ...
LAKEWOOD RANCH — Biotech company RPS Diagnostics announced Monday the publication of second U.S. clinical study that supports the accuracy of its 10-minute diagnostic test to identify acute bacterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results